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S U M M A R Y
Objectives: European surveillance studies have reported an increasing incidence of b-hemolytic group G
streptococcal bacteremia, but no studies have evaluated trends in b-hemolytic streptococcal bacteremia
in North America.
Methods: We reviewed bacteremic episodes and positive throat swab cultures from two tertiary care
centers in Manitoba, Canada, from January 2007 to December 2012.
Results: During the study period, 19 864 bacteremic episodes, and 9948 positive throat swabs were
identified. There were 1025 (5.16%) bacteremic episodes attributable to b-hemolytic streptococci: 425
(2.03%), 339 (1.71%), 62 (0.31%), and 199 (0.95%) to b-hemolytic groups A, B, C, and G streptococci,
respectively. From 2007 to 2012, there were significant increases in the proportion of bacteremia
attributable to b-hemolytic streptococci in general (6.32% vs. 4.02%; p < 0.0001; linear trend test,
p < 0.0001), and to groups G (1.49% vs. 0.43%; p < 0.0001; linear trend test, p < 0.0001) and C (0.58% vs.
0.13%; p = 0.0068; linear trend test, p = 0.0105) b-hemolytic streptococci in particular. Bacteremia
attributable to groups A and B b-hemolytic streptococci and Streptococcus pneumoniae were unchanged.
There were no changes in the distribution of b-hemolytic streptococcal groups among throat swabs.
Conclusions: Bacteremia attributable to b-hemolytic groups G and C streptococci increased in Manitoba,
Canada. Further study of the factors underlying these changes is required.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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b-Hemolytic streptococci cause skin and soft tissue infections,
bacteremia, and post-infectious immune-mediated sequelae in
humans. Bacteremia is relatively uncommon, but carries a grave
prognosis.1–3 The b-hemolytic streptococci most commonly
implicated in invasive human disease include Lancefield groups
A (GAS), B (GBS), C (GCS), and G (GGS). Recent evidence has
suggested changing epidemiology of these infections, most notably
with GGS increasing in frequency, and in some centers surpassing
GAS as the predominant cause of invasive b-hemolytic strepto-
coccal infection.2,4* Corresponding author. Tel.: +1 204 977 5681; fax: +1 204 789 3926.
E-mail address: ilan.steven.schwartz@gmail.com (I.S. Schwartz).
http://dx.doi.org/10.1016/j.ijid.2014.03.1376
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).To date, there have been no reports on the trends of invasive b-
hemolytic streptococcal infections from North America. We
hypothesized that the proportion of bacteremia attributable to
GGS has been increasing, that changes in the proportion of
bacteremia attributable to b-hemolytic streptococcal groups
would be mirrored by changes in the proportion of those groups
isolated from oropharyngeal specimens, and that these changes
would be accompanied by a decrease in bacteremia attributable to
Streptococcus pneumoniae.
2. Methods
Data were compiled from two tertiary care centers in Manitoba,
Canada, for the period 2007 to 2012 in order to determine the
frequency of bacteremia caused by GAS, GBS, GCS, and GGS. St.
Boniface General Hospital and Health Sciences Centre are tertiaryciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Number of episodes of bacteremia attributable to b-hemolytic streptococci, Streptococcus pneumoniae, and the total from all organisms, and the number of clinically
submitted throat swabs from which b-hemolytic streptococci were isolated, by group, 2007–2012
Source
Blood cultures Throat swabs
GAS (%) GBS (%) GCS (%) GGS (%) Total bHS
(%)
S. pneumoniae
(%)
Total episodes of
bacteremia
GAS (%) GCS (%) GGS (%) Total positive
throat swabs
2007 58 (1.92) 46 (1.53) 4 (0.13) 13 (0.43) 121 (4.02) 73 (2.42) 3013 1575 (82.72) 131 (6.88) 198 (10.40) 1904
2008 53 (1.76) 44 (1.46) 10 (0.33) 23 (0.76) 130 (4.31) 78 (2.58) 3018 1200 (80.00) 128 (8.53) 172 (11.47) 1500
2009 85 (2.67) 44 (1.38) 5 (0.16) 27 (0.85) 161 (5.05) 94 (2.95) 3189 1428 (81.00) 144 (8.17) 191 (10.83) 1763
2010 71 (2.06) 76 (2.21) 11 (0.32) 30 (0.87) 188 (5.46) 141 (4.09) 3444 1134 (80.48) 124 (8.80) 151 (10.72) 1409
2011 74 (2.07) 59 (1.65) 11 (0.31) 52 (1.45) 196 (5.48) 105 (2.94) 3574 1355 (83.28) 149 (9.16) 123 (7.56) 1627
2012 84 (2.32) 70 (1.93) 21 (0.58) 54 (1.49) 229 (6.32) 133 (3.67) 3626 1488 (85.27) 139 (7.97) 118 (6.76) 1745
Total 425 (2.14) 339 (1.71) 62 (0.31) 199 (1.00) 1025 (5.16) 624 (3.14) 19 864 8180 (82.22) 815 (8.19) 953 (9.58) 9948
GAS, group A b-hemolytic streptococci; GBS, group B b-hemolytic streptococci; GCS, group C b-hemolytic streptococci; GGS, group G b-hemolytic streptococci; bHS, b-
hemolytic streptococci.
0.00%
1.00%
2.00%
3.00%
4.00%
5.00%
6.00%
7.00%
2007 200 8 2009 201 0 201 1 2012
P
ro
po
rti
on
 o
f P
os
iti
ve
 B
lo
od
 C
ul
tu
re
s
A
GAS
GBS
GCS
GGS
Total 
βHS
p=0.152
p=0.0738  
p=0.0105
p<0.0001
p<0.0001
0.00%
1.00%
2.00%
3.00%
4.00%
5.00%
6.00%
7.00%
2007 200 8 2009 2010 201 1 201 2
P
ro
po
rti
on
 o
f P
os
iti
ve
 B
lo
od
 C
ul
tu
re
s
B
Figure 1. (A) Proportion of bacteremia attributable to b-hemolytic streptococci, in
total and by Lancefield grouping, from 2007 to 2012; (B) with linear trends.
(Abbreviations: GAS: b-hemolytic group A streptococci; GBS: b-hemolytic group B
streptococci; GCS: b-hemolytic group C streptococci; GGS: b-hemolytic group G
streptococci; bHS: b-hemolytic streptococci.).
I.S. Schwartz et al. / International Journal of Infectious Diseases 28 (2014) 211–213212care hospitals in Winnipeg, Manitoba, with a combined 1440 inpa-
tient beds, serving a population of 1.2 million people in a
catchment area including all of Manitoba and parts of western
Ontario and the territory of Nunavut.
Where multiple blood cultures were positive for the same
organism from the same patient within 6 months, only one was
counted. Because of increased specimens processed through the
study period, frequencies were calculated as a proportion of total
positive blood cultures. The difference in annual relative propor-
tions of groups was tested with a multinomial logistic model.
Within each group, temporal changes were assessed using linear
trend tests derived from logistic regression models with calendar
year as the sole predictor. Post-hoc comparisons between years
were also calculated for each model. Analyses were performed
with SAS version 9.3 (SAS Institute, Cary, NC, USA).
Blood cultures were incubated using the BacT/ALERT 3D
automated microbial detection system (bioMe´rieux, Marcy l’Etoile,
France) with aerobic (BacT/ALERT FA) and/or anaerobic (BacT/
ALERT FN) media, or BacT/ALERT pediatric FAN media. Positive
blood culture bottles with Gram-positive cocci observed on Gram
stain were plated to sheep’s blood, chocolate, and Brucella with
vitamin K agars, and incubated at 35 8C under aerobic, CO2, or
anaerobic conditions (in anaerobic jars with AnaeroGen gas-
generating packs; Oxoid, Basingstoke, UK). Gram-positive cocci
that were catalase-negative demonstrating b-hemolysis on blood
agar were tested for latex agglutination using a PathoDX Strep
Grouping Kit (Thermo Fisher Scientific, Lenexa, KS, USA) and the
methylumbelliferyl b-glucuronide (MUG) test for GCS and GGS.
Gram-positive cocci demonstrating a-hemolysis with colonies
typical for S. pneumoniae were confirmed with a bile solubility test.
These protocols are in accordance with Clinical and Laboratory
Standards Institute guidelines.5
In order to determine if trends in b-hemolytic streptococcal
bacteremia reflected changing trends in b-hemolytic streptococcal
oropharyngeal infection, we also reviewed all throat swab cultures
obtained during the study period. Throat swabs were inoculated to
blood agar plates, incubated aerobically at 35 8C for 18–24 h, and
any growth that appeared consistent with b-hemolytic strepto-
cocci (based on hemolysis pattern and colony morphology) was
confirmed as Streptococcus using catalase; grouping was then
done using latex agglutination and MUG tests.
3. Results and discussion
We reviewed 19 864 positive blood cultures, including 1025
(5.16%) episodes of bacteremia attributable to b-hemolytic
streptococci (Table 1). Changes in the relative proportions of
bacteremia attributable to b-hemolytic streptococci in total and by
Lancefield grouping over the study period are shown in Figure 1A;linear trends are displayed in Figure 1B. The proportion of
bacteremia attributable to b-hemolytic streptococci increased
significantly (2007 vs. 2012, p < 0.0001). There were significant
increases in the proportion of bacteremia attributable to GCS
(2007 vs. 2012, p = 0.0068) and GGS (2007 vs. 2012, p < 0.0001).
There was no significant change in the proportion of bacteremia
attributable to GAS (2007 vs. 2012, p = 0.2729) or GBS (2007 vs.
2012, p = 0.2123).
Our observation of an increase in bacteremia attributable to
GGS is consistent with reports from Europe, where an increasing
incidence of GGS bacteremia was observed in Finland from 1995 to
20046 and in Denmark from 1999 to 20027 and from 2005 to 2011,8
and also Jerusalem, Israel throughout the 1990s.4 Conversely,
I.S. Schwartz et al. / International Journal of Infectious Diseases 28 (2014) 211–213 213stable rates of GGS bacteremia have been reported from another
Jerusalem hospital over this same period,9 and from North
Queensland, Australia from 1996 to 2000.10
Our finding of an increasing proportion of bacteremia
attributable to GCS over the study period is consistent with the
findings of a large national surveillance study from Denmark for
the years 2005–2011.8 In contrast, most other investigators have
reported no significant change,1,2,6,7,10,11 a discrepancy which may
result from smaller studies being underpowered.
We further tested whether the observed changes were also
associated with a decrease in S. pneumoniae bacteremia, perhaps
related to an increased uptake of the S. pneumoniae conjugate
vaccine, similar to the suggested inverse relationship of carriage
between Staphylococcus aureus and S. pneumoniae.12 We found no
significant changes in the proportion of bacteremia caused by S.
pneumoniae during the study period (2007 vs. 2012, p = 0.0038;
linear trend test, p = 0.1247).
A total of 9948 throat swabs yielded isolates of GAS, GCS, or GGS
(Table 1). There were no significant changes in the relative
proportions of these bacteria isolated from positive throat swabs
(p = 1.0, multinomial logistic model with year as predictor). Of
note, GBS was not routinely reported because it does not cause
pharyngitis. Furthermore, throat swabs would have been submit-
ted on suspicion of clinical pharyngitis and thus may not truly
reflect rates of asymptomatic carriage. Because throat swabs were
not matched to blood cultures, inferences of the relationship
between b-hemolytic streptococcal oropharyngeal and invasive
disease were limited.
This study is, to our knowledge, the first to examine trends in b-
hemolytic streptococcal bacteremia in North America, and is
supported by a large sample size. There were no changes
implemented to the methods of blood culture collection, incuba-
tion, or identification of the b-hemolytic streptococci. Along with
trends reported elsewhere, this suggests that the changes observedrepresent changing epidemiology in b-hemolytic streptococcal
bacteremia.
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